BEAM
Price
$29.02
Change
+$2.17 (+8.08%)
Updated
Dec 20, 04:59 PM (EDT)
73 days until earnings call
JANX
Price
$56.71
Change
-$0.04 (-0.07%)
Updated
Dec 20, 04:59 PM (EDT)
76 days until earnings call
Ad is loading...

BEAM vs JANX

Header iconBEAM vs JANX Comparison
Open Charts BEAM vs JANXBanner chart's image
Beam Therapeutics
Price$29.02
Change+$2.17 (+8.08%)
Volume$37.3K
CapitalizationN/A
Janux Therapeutics
Price$56.71
Change-$0.04 (-0.07%)
Volume$32.89K
CapitalizationN/A
BEAM vs JANX Comparison Chart
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. JANX commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and JANX is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (BEAM: $29.04 vs. JANX: $56.71)
Brand notoriety: BEAM and JANX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 220% vs. JANX: 113%
Market capitalization -- BEAM: $2.22B vs. JANX: $3.33B
BEAM [@Biotechnology] is valued at $2.22B. JANX’s [@Biotechnology] market capitalization is $3.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 0 FA rating(s) are green whileJANX’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 0 green, 5 red.
  • JANX’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than JANX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while JANX’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 4 bearish.
  • JANX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, JANX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +3.97% price change this week, while JANX (@Biotechnology) price change was -7.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 04, 2025.

JANX is expected to report earnings on Mar 07, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JANX($3.33B) has a higher market cap than BEAM($2.22B). JANX YTD gains are higher at: 428.518 vs. BEAM (6.686). JANX has higher annual earnings (EBITDA): -83.88M vs. BEAM (-160.83M). BEAM has more cash in the bank: 926M vs. JANX (658M). JANX has less debt than BEAM: JANX (23.4M) vs BEAM (162M). BEAM has higher revenues than JANX: BEAM (350M) vs JANX (13M).
BEAMJANXBEAM / JANX
Capitalization2.22B3.33B67%
EBITDA-160.83M-83.88M192%
Gain YTD6.686428.5182%
P/E RatioN/AN/A-
Revenue350M13M2,692%
Total Cash926M658M141%
Total Debt162M23.4M692%
TECHNICAL ANALYSIS
Technical Analysis
BEAMJANX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 11 days ago
88%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 6 days ago
87%
View a ticker or compare two or three
Ad is loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ATGYX42.570.67
+1.60%
Cantor Fitzgerald Equity Opp Inst
MFEKX206.671.82
+0.89%
MFS Growth R6
SMERX12.750.08
+0.63%
Invesco Small Cap Equity R
JHTAX19.26N/A
N/A
JPMorgan Hedged Equity 3 A
VDSRX21.88N/A
N/A
Victory Diversified Stock R6

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+8.16%
CRSP - BEAM
72%
Closely correlated
+0.83%
NTLA - BEAM
66%
Loosely correlated
+1.08%
DNLI - BEAM
64%
Loosely correlated
-0.14%
PRME - BEAM
62%
Loosely correlated
+4.66%
RXRX - BEAM
61%
Loosely correlated
-0.90%
More

JANX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with VKTX. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
-0.07%
VKTX - JANX
61%
Loosely correlated
+1.83%
DNLI - JANX
49%
Loosely correlated
-0.14%
LGND - JANX
41%
Loosely correlated
+0.56%
CDXS - JANX
40%
Loosely correlated
+3.13%
SKYE - JANX
38%
Loosely correlated
-4.90%
More